Ursa Fund Management LLC acquired a new stake in DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS – Get Rating) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 25,000 shares of the company's stock, valued at approximately $243,000. Ursa Fund Management LLC owned about 0.10% of DA32 Life Science Tech Acquisition as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Radcliffe Capital Management L.P. acquired a new stake in shares of DA32 Life Science Tech Acquisition in the first quarter valued at approximately $1,420,000. Saba Capital Management L.P. acquired a new stake in shares of DA32 Life Science Tech Acquisition in the first quarter valued at approximately $10,883,000. Fir Tree Capital Management LP acquired a new stake in DA32 Life Science Tech Acquisition during the 1st quarter worth approximately $758,000. RP Investment Advisors LP lifted its holdings in DA32 Life Science Tech Acquisition by 653.1% during the 1st quarter. RP Investment Advisors LP now owns 408,856 shares of the company's stock worth $3,972,000 after purchasing an additional 354,569 shares during the last quarter. Finally, Verition Fund Management LLC acquired a new stake in DA32 Life Science Tech Acquisition during the 1st quarter worth approximately $917,000. 60.43% of the stock is owned by institutional investors and hedge funds.

DA32 Life Science Tech Acquisition Price Performance

NASDAQ:DALS opened at $9.74 on Wednesday. The stock has a 50 day simple moving average of $9.72 and a 200 day simple moving average of $9.71. DA32 Life Science Tech Acquisition Corp. has a 1-year low of $9.58 and a 1-year high of $10.26.

About DA32 Life Science Tech Acquisition

DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors.

See Also

• Get a free copy of the StockNews.com research report on DA32 Life Science Tech Acquisition (DALS)
• Is Five Below Trying to Punch Too High?
• These 3 Reports Will Tell Us Much About the Current Economy
• This Is What To Expect From The S&P 500 Now
• The Two Things You Need To Know About Oracle's FQ1 Report
• Three Value Stocks For A Volatile Market

Want to see what other hedge funds are holding DALS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS – Get Rating).

Receive News & Ratings for DA32 Life Science Tech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DA32 Life Science Tech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.